HIVe Home
Posted: 19 Sep 2011
AIDS Vaccine 2011 Day 2

Categories: news

Following the exciting announcement of the RV144 case-controlled study results on Tuesday, AIDS Vaccine 2011 featured further advances in basic science.  Highlights from Day 2 of AIDS Vaccine 2011 include:

  • Peter Kwong’s presentation on how to rationally guide antibody affinity maturation by designing immunogens that bind to VRC01 germline antibody. This gives hope to the feasibility of developing broadly neutralizing antibodies that need high affinity maturation such as VRC01. (P. Kwong S02.04)
  • The Vaccine Research Center’s plan to use passive immunization with VRC01, which included Phase I studies in HIV infected and uninfected adults as well as in uninfected infants to test safety and pharmacokinetics of VRC01 administration.  A Phase IIb study to assess the effect on protection in infants is scheduled for mid 2013. (B. Graham S04.01)
  • Issues around bridging and sustaining community partners, including ethical recommendations for care in HIV vaccine trials (C. Slack S01.03) and the need to adapt the community engagement agenda to ensure preparedness for today’s challenges.  (A. Menezes S01.04)
  • Robin Shattock’s presentation of evidence for different protective mechanisms for non-neutralizing antibodies. (R. Shattock, S02.03)
  • Bob Gallo’s update on a vaccine candidate designed to induce antibodies to CD4-induced (CD4i) epitopes, developed by the Institute of Human Virology, which showed two types of protection observed in NHP studies.  And his admitted mistake in co-authoring the letter published in Science that expressed concerns about the scientific rationale for RV144. (B. Gallo S02.02)
  • Additional information on the role of V2 reactive antibodies in RV144.  (S. Zolla-Pazner OA09.05)
  • The need to incorporate genetics into animal models to, among many things, account for the impact of TRIM5 polymorphism in non human primate studies.  (W. Johnson S03.05)

If you missed the session, check out the webcasts

  • Plenary 2 on New Prevention Strategies discussed the implications of ARV-based prevention strategies on efficacy endpoint of vaccine trials, circumcision and the necessity of a pediatric vaccine against HIV.

Conference abstracts

  • Abstracts presented at AIDS Vaccine 2011 have been published online in AIDS Research and Human Retroviruses and are available here

 Other conference highlights: